Data updated: Mar 10, 2026
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES
POLYETHYLENE GLYCOL 3350
Approved 2010-02-25
2
Indications
--
Phase 3 Trials
16
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2010-02-25
- Routes
- ORAL
- Dosage Forms
- FOR SOLUTION
Companies
Active Ingredient: POLYETHYLENE GLYCOL 3350 , POTASSIUM CHLORIDE , SODIUM BICARBONATE , SODIUM CHLORIDE , SODIUM SULFATE ANHYDROUS
Website: ↗
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES Approval History
Loading approval history...
What POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES Treats
2 FDA approvalsOriginally approved for its first indication in 2010 . Covers 2 distinct patient populations.
- Other (2)
Other
(2 approvals)- • Approved indication (Feb 2010)
- • Approved indication (Dec 2018)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.